Search
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigational[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251] … Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalAglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.
Rabies virus inactivated antigen, A
go.drugbank.com/drugs/DB10283ApprovedInvestigationalIt is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus. … Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection.
Products: ABHAYRAB 2.5 IU/0.5 ML IM/ID ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 1 ADETMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the … It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Categories: CCR5 Receptor Antagonists, CCR5 Co-receptor AntagonistPancrelipase
go.drugbank.com/drugs/DB00085ApprovedInvestigational[L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147]. … [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.
Products: PANZYTRAT OK MA RE MICROTA, CREON® CAPSULAS DE LIBERACION RETARADADA 10.000Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalNerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. … [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]
Papaverine
go.drugbank.com/drugs/DB01113ApprovedInvestigationalAn alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. … It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation.
Products: PAPAVERINA HE' TEOFARMA, PAPAVERINA RITARDO LIRCAPS HE'Salmon calcitonin
go.drugbank.com/drugs/DB00017ApprovedInvestigationalSynthetic peptide, 32 residues long formulated as a nasal spray.
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[L39367] In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen … [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017.
Sofpironium
go.drugbank.com/drugs/DB19325Approved[L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis. … [A264153] Sofpironium is rapidly converted to a less active metabolite, BBI-4010, after exerting its activity, thereby limiting the incidence and/or severity of systemic anticholinergic effects.